Gary Drizin, MD
Pulmonary Disease · Twin Falls, IDNPI 1700848140
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 181 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 19.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,155 and has fallen 94.2% since, to $126 in 2023.
Across 181 payments — averaging $18.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$651
- AstraZeneca$648
- Boehringer Ingelheim$293
- Regeneron Healthcare Solutions, Inc.$283
- Philips North America LLC$236
- Mylan Specialty L.p.$188
- plus $1K from 18 others
What the payments were for
- Food & beverage$3,398100%
- Education$90%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 46 | $651 |
| AstraZeneca(2 entities) | 30 | $648 |
| Boehringer Ingelheim | 14 | $293 |
| Regeneron Healthcare Solutions, Inc. | 11 | $283 |
| Philips North America LLC | 12 | $236 |
| Mylan Specialty L.p. | 11 | $188 |
| Mallinckrodt Enterprises LLC | 8 | $175 |
| Jazz Pharmaceuticals Inc. | 7 | $139 |
| Insmed, Inc. | 5 | $130 |
| Genentech USA, Inc. | 6 | $111 |
| Mallinckrodt Hospital Products Inc. | 3 | $79 |
| Sunovion Pharmaceuticals Inc. | 5 | $68 |
| Circassia Inc. | 3 | $53 |
| Resmed Corp | 3 | $50 |
| Grifols USA, LLC | 2 | $47 |
| United Therapeutics Corporation | 2 | $45 |
| Actelion Pharmaceuticals US, Inc. | 2 | $43 |
| Sanofi | 2 | $34 |
| Harmony Biosciences LLC | 2 | $32 |
| Pfizer | 2 | $31 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $25 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Electromed, Inc. | 2 | $14 |
| Johnson & Johnson | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SYMBICORT$225
- DUPIXENT$120
- BEVESPI AEROSPHERE$110
- FASENRA$110
How this compares
$3,407 in reported general payments places this provider in the 75th percentile of 57 pulmonary disease providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 278 | $225,178 |
| OfevNintedanib Esylate | 16 | $209,592 |
| Breo ElliptaFluticasone/Vilanterol | 84 | $43,711 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 74 | $43,035 |
| Incruse ElliptaUmeclidinium Bromide | 70 | $27,185 |
| Spiriva HandihalerTiotropium Bromide | 19 | $22,244 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 32 | $19,262 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 20 | $16,979 |
| SymbicortBudesonide/Formoterol Fumarate | 36 | $12,375 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 72 | $8,036 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 14 | $7,829 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 278 | $6,567 |
| Arnuity ElliptaFluticasone Furoate | 24 | $6,119 |
| Advair HfaFluticasone Propion/Salmeterol | 19 | $5,938 |
| Qvar RedihalerBeclomethasone Dipropionate | 13 | $3,599 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $651 | $345,228530 claims |
| Boehringer IngelheimOfev, Stiolto Respimat, Combivent Respimat, Striverdi Respimat | $293 | $237,40062 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $648 | $31,63768 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 57 pulmonary disease providers in Idaho.
Other pulmonary disease in Twin Falls
- Shawn FrenchTwin Falls$26K
- Gregory BallTwin Falls$6K
- Joseph EzerTwin Falls$0
- Todd HoopmanCoeur D Alene$76K
- Allen SalemIdaho Falls$44K
- Mark RasmusBoise$44K
- Karen MillerMeridian$12K
- Wesley PidcockNampa$12K
- Norman EastBoise$11K
- Jordan CormierIdaho Falls$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.